What Do Washington Reports Show About Reglan and Tardive Dyskinesia?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Targeted Legal Guidance

If you or someone you know has taken Reglan and noticed uncontrollable facial or body movements, you may be observing tardive dyskinesia. This page reviews documented reports and clinical patterns in Washington. The longstanding tradition of patient safety education has provided a foundation for understanding such medication risks, and here we focus on the specific signals reported in the state.

Understanding Reglan and Its Link to Tardive Dyskinesia

Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux that has not responded to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The prescribing information explicitly states that Reglan has not been shown to be safe and effective for treating gastroesophageal reflux for longer than 12 weeks, and it is not recommended for use in pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is a potentially irreversible serious movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities. The FDA-approved boxed warning for Reglan states that metoclopramide can cause TD, and the risk increases with longer duration of treatment and higher total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning further notes that Reglan is contraindicated in patients with a history of TD, and that the medication should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be discontinued immediately (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves metoclopramide's dopamine D2 receptor antagonism in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. The prescribing information also warns that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect is particularly concerning because it may allow TD to progress unnoticed until it becomes more severe or irreversible.

Statute of Limitations for Reglan Claims in Washington

For patients in Washington who have developed TD after using Reglan, several attorney-related considerations are relevant. The statute of limitations for personal injury claims in Washington is generally three years from the date the injury was discovered or should have been discovered with reasonable diligence. However, the timeline between exposure to Reglan and the onset of TD can be variable, and the condition may develop months or even years after starting the medication. The boxed warning emphasizes that the risk of TD increases with duration of treatment and total cumulative dosage, meaning that patients who used Reglan for longer than the recommended 12-week maximum are at higher risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, the label advises avoiding total treatment duration longer than 12 weeks, but if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Adequacy of warnings is a key risk anchor in potential legal claims. The FDA-approved labeling includes a boxed warning that clearly states the risk of TD, the importance of short-term use, and the need for immediate discontinuation if symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, questions may arise about whether prescribers and patients were adequately informed about the specific risks, especially in cases where Reglan was used off-label or for extended periods. The label also warns against concomitant use of other drugs known to cause TD, extrapyramidal symptoms, or neuroleptic malignant syndrome, and advises avoiding use in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For affected patients in Washington, it is important to document the timeline of Reglan use, including start and stop dates, dosages, and any symptoms of TD that developed. Medical records should be reviewed to determine whether the prescribing physician followed the recommended duration limits and monitoring guidelines. If a patient developed TD after using Reglan for longer than 12 weeks, or if they were not warned about the risk of TD, these factors may support a legal claim. The statute of limitations clock typically starts when the patient knew or should have known that their TD was caused by Reglan, which may be later than the actual onset of symptoms due to the gradual nature of the condition.

Legal Considerations and Next Steps

In summary, Reglan carries a known risk of causing tardive dyskinesia, a potentially irreversible movement disorder, with risk increasing with longer use and higher doses. The FDA-approved labeling provides clear warnings about this risk and recommends short-term use only. Patients in Washington who developed TD after using Reglan should consult with an attorney to evaluate their case, considering the statute of limitations, the adequacy of warnings they received, and the timeline between exposure and harm. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in Washington?

In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or should have been discovered with reasonable diligence. For tardive dyskinesia caused by Reglan, the clock may start when the patient knew or should have known that their TD was linked to the medication.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) blocks dopamine D2 receptors in the basal ganglia, leading to dopamine receptor supersensitivity and involuntary movements characteristic of tardive dyskinesia. The risk increases with longer use and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.